Investor Relations
| MNTA - (NASDAQ) $15.19 + 0.06 | Jan 27, 2012 4:00 PM ET |
Momenta Pharmaceuticals is a biotechnology company based in Cambridge, MA focused on the development of complex generics, follow-on biologics and novel drugs. In July 2010, the Company's lead product, enoxaparin sodium injection, (developed with collaboration partner Sandoz) was approved as the first generic version of Lovenox®. The Company's development pipeline includes a generic version of Copaxone, also partnered with Sandoz, follow-on biologic candidates, M118, a rationally designed low molecular weight heparin with improved therapeutic potential, and M402, a heparin-based oncology candidate in preclinical development.
View Annual Report and Proxy Material
Recent Releases
Quotes delayed at least 20 minutes. Information provided by eSignal.

